This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
In spite of vast sums and considerable effort, the treatment of strokes remains unsatisfactory. Ingenious methods have been devised to measure cerebral blood flow, and these have yielded a wealth of information which, however, has yet to find use in the management of stroke. No wonder, then, when a pill reputed to increase cerebral blood flow is marketed, international symposia are soon organized to review its efficiency in the treatment of stroke.
The gathering was large and scientifically undistinguished; the papers ranged appropriately from anecdotal to uncontrolled studies. Reaction times were studied before and after cyclandelate therapy, and any changes were taken to equate with cortical functional improvement. Most authors limited themselves to patients with so-called arteriosclerotic dementia. No allowance was made for the incredible variety of deficits often found in such patients. Double-blind studies of the effects of cyclandelate were not particularly favored, and the effects of continuation or
Appenzeller O. Assessment in Cerebrovascular Insufficiency. Arch Neurol. 1971;25(3):286. doi:10.1001/archneur.1971.00490030112027
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.